Liu XJ, Lin YX, Chen LX, Yang WJ, Hu B. Multidisciplinary approaches in the management of advanced hepatocellular carcinoma: Exploring future directions. World J Gastrointest Oncol 2024; 16(10): 4052-4054 [DOI: 10.4251/wjgo.v16.i10.4052]
Corresponding Author of This Article
Bing Hu, MD, Professor, Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Wuhou District, Chengdu 610041, Sichuan Province, China. hubingnj@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Oct 15, 2024; 16(10): 4052-4054 Published online Oct 15, 2024. doi: 10.4251/wjgo.v16.i10.4052
Multidisciplinary approaches in the management of advanced hepatocellular carcinoma: Exploring future directions
Xin-Jin Liu, Yi-Xiu Lin, Liu-Xiang Chen, Wen-Juan Yang, Bing Hu
Xin-Jin Liu, Yi-Xiu Lin, Liu-Xiang Chen, Department of Gastroenterology and Hepatology/Medical Engineering Integration Laboratory of Digestive Endoscopy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Wen-Juan Yang, Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Bing Hu, Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Liu XJ drafted the manuscript; Lin YX, Chen LX, Yang WJ and Hu B revised the manuscript; All authors reviewed and approved the final manuscript.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bing Hu, MD, Professor, Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Wuhou District, Chengdu 610041, Sichuan Province, China. hubingnj@163.com
Received: March 24, 2024 Revised: May 14, 2024 Accepted: June 11, 2024 Published online: October 15, 2024 Processing time: 186 Days and 3.2 Hours
Abstract
Recently, we read the article “Pathologically successful conversion hepatectomy for advanced giant hepatocellular carcinoma after multidisciplinary therapy: A case report and review of the literature” published in the World Journal of Gastrointestinal Oncology. The prognosis of advanced hepatocellular carcinoma (HCC) is poor, and multidisciplinary comprehensive treatment is currently the main research direction. This case report demonstrated the efficacy of the combination therapy of transcatheter arterial chemoembolization, hepatic arterial infusion chemotherapy, epclusa, lenvatinib and sintilimab for a patient with advanced HCC, and the report can serve as a reference for clinical practice. We would also like to share some of our views.
Core Tip: Chu and colleagues reported a case of pathologically successful conversion hepatectomy for advanced giant hepatocellular carcinoma after multidisciplinary therapy. We shared our views about this study and discussed the current status of unresectable liver cancer. We believe that individualized combination therapy has great potential for patients with advanced liver cancer.
